Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Interest & Investment Income (2016 - 2026)

Amphastar Pharmaceuticals has reported Interest & Investment Income over the past 13 years, most recently at $2.4 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 5.72% year-over-year to $2.4 million; the TTM value through Dec 2025 reached $8.7 million, down 18.22%, while the annual FY2025 figure was $8.7 million, 18.22% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $2.4 million at Amphastar Pharmaceuticals, up from $2.2 million in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $3.3 million in Q2 2024 and troughed at $141000.0 in Q3 2021.
  • A 5-year average of $1.3 million and a median of $1.1 million in 2023 define the central range for Interest & Investment Income.
  • Biggest five-year swings in Interest & Investment Income: skyrocketed 410.5% in 2023 and later crashed 42.43% in 2025.
  • Year by year, Interest & Investment Income stood at $157000.0 in 2021, then soared by 269.43% to $580000.0 in 2022, then surged by 297.07% to $2.3 million in 2023, then fell by 0.48% to $2.3 million in 2024, then grew by 5.72% to $2.4 million in 2025.
  • Business Quant data shows Interest & Investment Income for AMPH at $2.4 million in Q4 2025, $2.2 million in Q3 2025, and $1.9 million in Q2 2025.